Ascletis Pharma Inc. ASCLF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Ascletis Pharma Inc. (ASCLF) , 前瞻盈利收益率 21.01%.

本頁證實的標準:

VALUE (0/100, 未通過) — 綜合估值評分低於60/100的通過門檻。
前瞻本益比 4.8

SharesGrow 綜合評分： 29/100 其中 0/7 項標準通過。

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

價值

N/A

No coverage

—

未來

N/A

No coverage

✗

過去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

護城河

62/100

→ Income

✗

成長

15/100

→ Income

✗

收入

10/100

→ Income

估值概覽 — ASCLF

估值倍數

P/E (TTM)0.0

前瞻 P/E4.8

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率1,639.39

EV/EBITDA0.0

每股數據

EPS (TTM)$-0.30

前瞻 EPS（預估）$0.44

每股帳面價值$0.00

每股營收$0.00

每股自由現金流$0.00

收益率與內在價值

盈利收益率N/A

Forward Earnings Yield21.01%

股息收益率0.00%

EPS：實際 vs 預期

P/E Ratio & Earnings Yield

每股盈餘 (EPS) 歷史

Year	EPS（稀釋）	營收	淨利潤	淨利潤率
2016	$-0.02	$32.98M	$-26.81M	-81.3%
2017	$-0.05	$53.2M	$-53.94M	-101.4%
2018	$-0.01	$166.33M	$-7.26M	-4.4%
2019	$-0.15	$173.44M	$-155.5M	-89.7%
2020	$-0.25	$35M	$-262.05M	-748.7%
2021	$-0.18	$76.88M	$-202.14M	-262.9%
2022	$-0.34	$54.09M	$-366.71M	-678%
2023	$-0.13	$56.6M	$-144.72M	-255.7%
2024	$-0.30	$1.28M	$-300.94M	-23455.7%